Witek Przemysław, Mucha Sławomir, Ruchała Marek
Department of Endocrinology and Isotope Therapy, Military Institute of Medicine, Warsaw, Poland.
Endokrynol Pol. 2016;67(6):572-579. doi: 10.5603/EP.2016.0066.
Despite the known importance of somatostatin analogues (SSAs) in the treatment of acromegaly, patient satisfaction leading to preferences for specific SSAs have received little attention so far.
This open, prospective, observational, multicentre patient-reported outcome study included adult patients with acromegaly, who switched from another SSA to lanreotide Autogel (new and previous devices) at least two months prior to enrolment. The observation period was around 12 months. The primary outcome assessed was overall treatment satisfaction, measured using the five-point Likert scale. The secondary outcomes were: 1) treatment effectiveness, in terms of symptom control; 2) technical problems related to treatment administration, measured by the Visual Analog Scale (VAS); and 3) ease and safety of lanreotide Autogel delivery (new device vs. previous device).
Of the 102 patients who completed the study, 97 (95.1%) were "completely or rather satisfied" with lanreotide Autogel therapy, four (3.9%) were "neither satisfied nor dissatisfied", and one (1%) was "rather dissatisfied". Symptom control was reported as "excellent" or "good" by 88-89% of patients throughout the study. Patients reported fewer technical problems related to administration of lanreotide Autogel (final mean VAS: 5.3) compared to previous SSAs (mean VAS: 37.6). Of the 31 patients treated with lanreotide Autogel using the previous device followed by the new device, 64.5% reported the new device as improved.
Lanreotide Autogel therapy resulted in greater patient satisfaction with overall acromegaly management, when compared to previous SSAs. The new lanreotide Autogel device was found to be easier to use than the previous one. (Endokrynol Pol 2016; 67 (6): 572-579).
尽管生长抑素类似物（SSAs）在肢端肥大症治疗中的重要性已为人所知，但患者满意度以及由此产生的对特定SSAs的偏好，目前很少受到关注。
这项开放性、前瞻性、观察性、多中心患者报告结局研究纳入了成年肢端肥大症患者，这些患者在入组前至少两个月从另一种SSA改用兰瑞肽缓释凝胶（新旧装置）。观察期约为12个月。评估的主要结局是总体治疗满意度，采用五点李克特量表进行测量。次要结局包括：1）症状控制方面的治疗效果；2）通过视觉模拟量表（VAS）测量的与治疗给药相关的技术问题；3）兰瑞肽缓释凝胶给药的便利性和安全性（新装置与旧装置）。
在完成研究的102例患者中，97例（95.1%）对兰瑞肽缓释凝胶治疗“完全满意或相当满意”，4例（3.9%）“既不满意也不不满意”，1例（1%）“相当不满意”。在整个研究过程中，88 - 89%的患者报告症状控制为 “优秀” 或 “良好”。与之前的SSAs相比，患者报告与兰瑞肽缓释凝胶给药相关的技术问题更少（最终平均VAS：5.3），而之前的SSAs平均VAS为37.6。在31例先用旧装置后用新装置接受兰瑞肽缓释凝胶治疗的患者中，64.5%报告新装置有所改进。
与之前的SSAs相比，兰瑞肽缓释凝胶治疗使患者对肢端肥大症的总体管理更满意。发现新的兰瑞肽缓释凝胶装置比旧装置更易于使用。（《波兰内分泌学》2016年；67(6)：572 - 579）
